selected publications
-
academic article
-
Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine..
Molecular Pharmaceutics.
15.
2018
Aspartame as a co-former in co-amorphous systems.
International Journal of Pharmaceutics.
549.
2018
Glass-Transition Temperature of the β-Relaxation as the Major Predictive Parameter for Recrystallization of Neat Amorphous Drugs..
The Journal of Physical Chemistry B.
122.
2018
In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium – a proof of concept study.
European Journal of Pharmaceutics and Biopharmaceutics.
133.
2018
In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
European Journal of Pharmaceutics and Biopharmaceutics.
132.
2018
Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.
Pharmaceutics.
10.
2018
Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids.
International Journal of Pharmaceutics.
552.
2018
Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?.
International Journal of Pharmaceutics.
538.
2018
On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
International Journal of Pharmaceutics.
535.
2018
Organic acids as co-formers for co-amorphous systems - influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
European Journal of Pharmaceutics and Biopharmaceutics.
131.
2018
The Influence of Polymers on the Supersaturation Potential of Poor and Good Glass Formers.
Pharmaceutics.
10.
2018
The Role of Glass Transition Temperatures in Coamorphous Drug-Amino Acid Formulations..
Molecular Pharmaceutics.
15.
2018
The use of molecular descriptors in the development of co-amorphous formulations.
European Journal of Pharmaceutical Sciences.
119.
2018
Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
International Journal of Pharmaceutics.
544.
2018
Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ.
International Journal of Pharmaceutics.
519.
2017
Correlation between calculated molecular descriptors of excipient amino acids and experimentally observed thermal stability of lysozyme.
International Journal of Pharmaceutics.
523.
2017
Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.
International Journal of Pharmaceutics.
526.
2017
Influence of preparation pathway on the glass forming ability.
International Journal of Pharmaceutics.
521.
2017
Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
International Journal of Pharmaceutics.
533.
2017
Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder..
Molecular Pharmaceutics.
14.
2017
Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
European Journal of Pharmaceutics and Biopharmaceutics.
119.
2017
Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.
International Journal of Pharmaceutics.
532.
2017
Surface area, volume and shape descriptors as a novel tool for polymer lead design and discovery.
European Journal of Pharmaceutical Sciences.
102.
2017
The significance of the amorphous potential energy landscape for dictating glassy dynamics and driving solid-state crystallisation.
Physical Chemistry Chemical Physics.
19.
2017
Development of a screening method for co-amorphous formulations of drugs and amino acids.
European Journal of Pharmaceutical Sciences.
95.
2016
Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation..
Molecular Pharmaceutics.
13.
2016
Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with Eudragit® E PO.
Journal of Drug Delivery Science and Technology.
34.
2016
Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
European Journal of Pharmaceutics and Biopharmaceutics.
109.
2016
Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
European Journal of Pharmaceutics and Biopharmaceutics.
107.
2016
Investigation of physical properties and stability of indomethacin–cimetidine and naproxen–cimetidine co‐amorphous systems prepared by quench cooling, coprecipitation and ball milling.
Journal of Pharmacy and Pharmacology.
68.
2016
Large-Scale Biophysical Evaluation of Protein PEGylation Effects: In Vitro Properties of 61 Protein Entities..
Molecular Pharmaceutics.
13.
2016
Preparation and characterization of spray‐dried co‐amorphous drug–amino acid salts.
Journal of Pharmacy and Pharmacology.
68.
2016
Preparation and recrystallization behavior of spray-dried co-amorphous naproxen–indomethacin.
European Journal of Pharmaceutics and Biopharmaceutics.
104.
2016
Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage.
Molecules.
21.
2016
Recent advances in co-amorphous drug formulations.
Advanced Drug Delivery Reviews.
100.
2016
Solvent free amorphisation for pediatric formulations (minitablets) using mesoporous silica.
International Journal of Pharmaceutics.
511.
2016
Unintended and in situ amorphisation of pharmaceuticals.
Advanced Drug Delivery Reviews.
100.
2016
Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
Molecules.
20.
2015
Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures..
Molecular Pharmaceutics.
12.
2015
Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.
Molecules.
20.
2015
Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine.
European Journal of Pharmaceutics and Biopharmaceutics.
96.
2015
Well-plate freeze-drying: a high throughput platform for screening of physical properties of freeze-dried formulations.
Pharmaceutical Development and Technology.
20.
2015
Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability..
Molecular Pharmaceutics.
11.
2014
Formation of mannitol hemihydrate in freeze-dried protein formulations—A design of experiment approach.
International Journal of Pharmaceutics.
460.
2014
Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline..
Pharmaceutics.
6.
2014
Near‐Infrared Imaging for High‐Throughput Screening of Moisture Induced Changes in Freeze‐Dried Formulations.
Journal of Pharmaceutical Sciences.
103.
2014
Refining stability and dissolution rate of amorphous drug formulations.
Expert Opinion on Drug Delivery.
11.
2014
-
chapter
-
Stabilized Amorphous Solid Dispersions with Small Molecule Excipients.
Springer Nature.
2014
Theoretical Considerations in Developing Amorphous Solid Dispersions.
Springer Nature.
2014
-
hide from search
-
A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin.
International Journal of Pharmaceutics.
2013
Amino acids as co-amorphous stabilizers for poorly water-soluble drugs – Part 2: Molecular interactions.
European Journal of Pharmaceutics and Biopharmaceutics.
2013
Detecting phase separation of freeze-dried binary amorphous systems using pair-wise distribution function and multivariate data analysis.
International Journal of Pharmaceutics.
2013
Emerging trends in the stabilization of amorphous drugs.
International Journal of Pharmaceutics.
2013
Erratum to: Design of Experiments-Based Monitoring of Critical Quality Attributes for the Spray-Drying Process of Insulin by NIR Spectroscopy.
AAPS PharmSciTech.
2013
Fuzzy Logic‐Based Expert System for Evaluating Cake Quality of Freeze‐Dried Formulations.
Journal of Pharmaceutical Sciences.
2013
In situ amorphisation of indomethacin with Eudragit® E during dissolution.
European Journal of Pharmaceutics and Biopharmaceutics.
2013
Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug–polymer mixtures.
International Journal of Pharmaceutics.
2013
The influence of lysozyme on mannitol polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying process.
International Journal of Pharmaceutics.
2013
-
patent
-
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE
2019
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN
2019
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN
2019
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE
2018
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN
2018
A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN
2018